A Phase 1a Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of OMP-313M32 Administered as a Single Agent to Subjects With Locally Advanced or Metastatic Solid Tumors

Trial Profile

A Phase 1a Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of OMP-313M32 Administered as a Single Agent to Subjects With Locally Advanced or Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jan 2018

At a glance

  • Drugs OMP 313M32 (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors OncoMed Pharmaceuticals
  • Most Recent Events

    • 04 Jan 2018 According to an OncoMed Pharmaceuticals media release, Anti-TIGIT data will be presented in 2018, subjects to progress of this trial.
    • 02 Nov 2017 According to an OncoMed Pharmaceuticals media release, interim data from phase 1a is expected to be reported by year-end 2018 and phase 1b portion of the study is expected to begin in the first half of 2018.
    • 09 May 2017 According to an OncoMed Pharmaceuticals media release, Johanna Bendell, M.D., Associate Director of the Drug Development Program at Sarah Cannon Research Institute is a lead investigator for the study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top